Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine maintenance therapy in AML and MDS (single-arm, multicenter, prospective)
ChiCTR2100052486Phase 4Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Huadong Hospital, Fudan University. Primary endpoint: Minimal residual disease. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2100052486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052486.